Under the expanded agreement, in addition to commercializing SensiGen’s advanced test for human papillomavirus exclusively on Sequenom’s MassArray platform, SensiGen will also be the exclusive provider of MassArray platform-based assays for SensiGen’s newly developed chronic kidney disease and lupus tests.
Sequenom will exclusively supply platform technology and reagents used for commercializing SensiGen’s proprietary tests. The expanded agreement also provides Sequenom with the future right to a minority equity interest in SensiGen.
Harry Stylli, president and CEO of Sequenom, said: “We believe this expanded alliance with SensiGen will enable us to offer a broader menu of MassArray platform-based products and services that meet the needs of clinical laboratory customers and provide significant value in the global healthcare marketplace.”